Review



cy34 1 130 102 576 cd27 pe  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Miltenyi Biotec cy34 1 130 102 576 cd27 pe
    Cy34 1 130 102 576 Cd27 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cy34 1 130 102 576 cd27 pe/product/Miltenyi Biotec
    Average 94 stars, based on 11 article reviews
    cy34 1 130 102 576 cd27 pe - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    94
    Miltenyi Biotec cy34 1 130 102 576 cd27 pe
    Cy34 1 130 102 576 Cd27 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cy34 1 130 102 576 cd27 pe/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cy34 1 130 102 576 cd27 pe - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Proteintech anti cd22
    Anti Cd22, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd22/product/Proteintech
    Average 94 stars, based on 1 article reviews
    anti cd22 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd22 apc
    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and <t>CD22</t> (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.
    Cd22 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd22 apc/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cd22 apc - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec anti cd22 pe vio615
    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and <t>CD22</t> (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.
    Anti Cd22 Pe Vio615, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd22 pe vio615/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    anti cd22 pe vio615 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd22 antibody, anti-mouse, reafinity
    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and <t>CD22</t> (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.
    Cd22 Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd22 antibody, anti-mouse, reafinity/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    cd22 antibody, anti-mouse, reafinity - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    90
    Bio X Cell rat anti-mouse cd19 and cd22
    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and <t>CD22</t> (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.
    Rat Anti Mouse Cd19 And Cd22, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti-mouse cd19 and cd22/product/Bio X Cell
    Average 90 stars, based on 1 article reviews
    rat anti-mouse cd19 and cd22 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    94
    fluidigm gd cd23 ebvcs5 fluidigm 3160020b 161 dy cd22 hib22 biolegend
    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and <t>CD22</t> (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.
    Gd Cd23 Ebvcs5 Fluidigm 3160020b 161 Dy Cd22 Hib22 Biolegend, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gd cd23 ebvcs5 fluidigm 3160020b 161 dy cd22 hib22 biolegend/product/fluidigm
    Average 94 stars, based on 1 article reviews
    gd cd23 ebvcs5 fluidigm 3160020b 161 dy cd22 hib22 biolegend - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    Sangon Biotech anti-cd22 antibody
    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and <t>CD22</t> (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.
    Anti Cd22 Antibody, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd22 antibody/product/Sangon Biotech
    Average 90 stars, based on 1 article reviews
    anti-cd22 antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and CD22 (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.

    Journal: Frontiers in Genome Editing

    Article Title: CRISPR-mediated generation of a tumor-associated antigen-deficient Raji platform to investigate antigen loss in CAR-T cell therapy

    doi: 10.3389/fgeed.2025.1649993

    Figure Lengend Snippet: Genomic deletion of target antigens in Raji-Luc lines does not alter proliferation or viability. (A) Schematic representation of CRISPR-Cas9–mediated strategy to generate single, double, and triple knockout (KO) Raji-Luc cell lines. (B–D) Amplicon sequencing data showing genomic deletions at the CD19 (B) , CD20 (C) , and CD22 (D) loci in the respective KO lines, confirming targeted gene disruption. (E) Proliferation assay comparing all the Raji-Luc KO lines and control Raji-Luc-WT over 96 h. Data plotted as fold change normalized to Raji WT. (F) Viability analysis after 2 h incubation with AlamarBlue reveals no significant differences between Raji WT, Raji-Luc WT, and KO lines. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. *, p < 0.05; ns = not significant.

    Article Snippet: For CD19 and CD22 staining, cells were incubated with CD19-PE (Miltenyi Biotec) and CD22-APC (Miltenyi Biotec) antibodies for 30 min at 4 °C in the dark.

    Techniques: CRISPR, Triple Knockout, Amplification, Sequencing, Disruption, Proliferation Assay, Control, Incubation

    Raji knockout lines generated via CRISPR-Cas9 exhibit complete loss of CD19, CD20, and CD22 transcript and protein expression. (A–C) Transcript level analysis via qRT-PCR revealed significant reduction in the mRNA levels of (A) CD19, (B) CD20 and (C) CD22. K562 was used as CD-marker negative control. Gene expression was normalized to Raji WT and GAPDH was used as an internal control. Data plotted as fold change (mean ± SD, n = 3). (D) Immunofluorescence staining for CD19 (yellow), CD20 (green), CD22 (red), and Hoechst (blue) in all Raji cell lines and K562. Loss of surface antigen staining is evident in all corresponding knockout lines. Images are representative of three independent experiments. Scale bar = 50 μm. (E–G) Flow cytometry analysis of surface CD19 (E) , CD20 (F) , and CD22 (G) expression in nonpermeabilized Raji-derived knockout cells and K562 control. Data represent mean ± SD of fluorescence intensity (MFI) from three independent experiments, confirming complete loss of surface expression of the respective target antigen in each knockout line. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. ****, p < 0.0001; ***, p < 0.001; ns = not significant.

    Journal: Frontiers in Genome Editing

    Article Title: CRISPR-mediated generation of a tumor-associated antigen-deficient Raji platform to investigate antigen loss in CAR-T cell therapy

    doi: 10.3389/fgeed.2025.1649993

    Figure Lengend Snippet: Raji knockout lines generated via CRISPR-Cas9 exhibit complete loss of CD19, CD20, and CD22 transcript and protein expression. (A–C) Transcript level analysis via qRT-PCR revealed significant reduction in the mRNA levels of (A) CD19, (B) CD20 and (C) CD22. K562 was used as CD-marker negative control. Gene expression was normalized to Raji WT and GAPDH was used as an internal control. Data plotted as fold change (mean ± SD, n = 3). (D) Immunofluorescence staining for CD19 (yellow), CD20 (green), CD22 (red), and Hoechst (blue) in all Raji cell lines and K562. Loss of surface antigen staining is evident in all corresponding knockout lines. Images are representative of three independent experiments. Scale bar = 50 μm. (E–G) Flow cytometry analysis of surface CD19 (E) , CD20 (F) , and CD22 (G) expression in nonpermeabilized Raji-derived knockout cells and K562 control. Data represent mean ± SD of fluorescence intensity (MFI) from three independent experiments, confirming complete loss of surface expression of the respective target antigen in each knockout line. Statistical analysis was performed using ordinary one-way ANOVA followed by the Dunnett’s multiple comparisons test. ****, p < 0.0001; ***, p < 0.001; ns = not significant.

    Article Snippet: For CD19 and CD22 staining, cells were incubated with CD19-PE (Miltenyi Biotec) and CD22-APC (Miltenyi Biotec) antibodies for 30 min at 4 °C in the dark.

    Techniques: Knock-Out, Generated, CRISPR, Expressing, Quantitative RT-PCR, Marker, Negative Control, Gene Expression, Control, Immunofluorescence, Staining, Flow Cytometry, Derivative Assay, Fluorescence

    Raji KO lines model antigen loss and resist CAR-T cell–mediated cytotoxicity. (A) Schematic representation of CAR constructs targeting CD19, CD20, and CD22. (B) Flow cytometric analysis of isolated T cells confirmed the expression of T cell–specific markers and negligible expression of non–T cell markers. (C) Expression of T-cell activation markers on isolated T cells post 48 h of activation with CD3/CD28 beads. (D) Flow cytometry of GFP expression in T cells 48 h post-transduction. Histogram shown from one of three independent transductions using T cells from three different donors. (E–G) Viability of Raji KO lines assessed by bioluminescence following 16 h co-culture with CAR T cells expressing CAR19 (E) , CAR20 (F) or CAR22 (G) at indicated effector-to-target (E:T) ratios. Percent live cells was calculated based on luminescence signal relative to target-only control and normalized to untransduced controls. CAR-T cells selectively eliminated WT Raji cells expressing the corresponding target antigen, while respective single, double, and triple KO lines remained resistant. K562 cells served as antigen negative control. Data are presented as mean ± SD for three independent biological replicates. Statistical analysis was performed using multiple unpaired t-tests (one per row) with Holm–Šidák correction for multiple comparisons (C) or by comparing area under the curve for each cell line group in an ordinary one-way ANOVA with Dunnett’s multiple comparisons test (E–G) . ***, p < 0.001; ****, p < 0.0001; ns = not significant.

    Journal: Frontiers in Genome Editing

    Article Title: CRISPR-mediated generation of a tumor-associated antigen-deficient Raji platform to investigate antigen loss in CAR-T cell therapy

    doi: 10.3389/fgeed.2025.1649993

    Figure Lengend Snippet: Raji KO lines model antigen loss and resist CAR-T cell–mediated cytotoxicity. (A) Schematic representation of CAR constructs targeting CD19, CD20, and CD22. (B) Flow cytometric analysis of isolated T cells confirmed the expression of T cell–specific markers and negligible expression of non–T cell markers. (C) Expression of T-cell activation markers on isolated T cells post 48 h of activation with CD3/CD28 beads. (D) Flow cytometry of GFP expression in T cells 48 h post-transduction. Histogram shown from one of three independent transductions using T cells from three different donors. (E–G) Viability of Raji KO lines assessed by bioluminescence following 16 h co-culture with CAR T cells expressing CAR19 (E) , CAR20 (F) or CAR22 (G) at indicated effector-to-target (E:T) ratios. Percent live cells was calculated based on luminescence signal relative to target-only control and normalized to untransduced controls. CAR-T cells selectively eliminated WT Raji cells expressing the corresponding target antigen, while respective single, double, and triple KO lines remained resistant. K562 cells served as antigen negative control. Data are presented as mean ± SD for three independent biological replicates. Statistical analysis was performed using multiple unpaired t-tests (one per row) with Holm–Šidák correction for multiple comparisons (C) or by comparing area under the curve for each cell line group in an ordinary one-way ANOVA with Dunnett’s multiple comparisons test (E–G) . ***, p < 0.001; ****, p < 0.0001; ns = not significant.

    Article Snippet: For CD19 and CD22 staining, cells were incubated with CD19-PE (Miltenyi Biotec) and CD22-APC (Miltenyi Biotec) antibodies for 30 min at 4 °C in the dark.

    Techniques: Construct, Isolation, Expressing, Activation Assay, Flow Cytometry, Transduction, Co-Culture Assay, Control, Negative Control